| Dr Mel Angelo Ona, MD, MS, MPH, MA | |
|
590 Farrington Hwy Unit 526a, Kapolei, HI 96707-2034 | |
| (808) 762-2311 | |
| (808) 376-8780 |
| Full Name | Dr Mel Angelo Ona |
|---|---|
| Gender | Male |
| Speciality | Gastroenterology |
| Experience | 15 Years |
| Location | 590 Farrington Hwy Unit 526a, Kapolei, Hawaii |
| Accepts Medicare Assignments | May be. He may accept the Medicare-approved amount; you may be billed for more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1720318199 | NPI | - | NPPES |
| 816548 | Medicaid | HI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207R00000X | Internal Medicine | 266590 (New York) | Secondary |
| 207RG0100X | Internal Medicine - Gastroenterology | MD-19048 (Hawaii) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Pali Momi Medical Center | Aiea, HI | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mel A Ona M D Incorporated | 9335489442 | 3 |
News Archive
Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.
Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
› Verified 7 days ago
| Entity Name | Hawaii Gastroenterology Specialist |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1790033454 PECOS PAC ID: 7618120437 Enrollment ID: O20130103000326 |
News Archive
Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.
Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
› Verified 7 days ago
| Entity Name | Mel A Ona M D Incorporated |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710459300 PECOS PAC ID: 9335489442 Enrollment ID: O20190327000073 |
News Archive
Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.
Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mel Angelo Ona, MD, MS, MPH, MA 590 Farrington Hwy Unit 526a, Kapolei, HI 96707-2034 Ph: (617) 319-4441 | Dr Mel Angelo Ona, MD, MS, MPH, MA 590 Farrington Hwy Unit 526a, Kapolei, HI 96707-2034 Ph: (808) 762-2311 |
News Archive
Bausch + Lomb, the global eye health company, and Technolas Perfect Vision GmbH, a leading ophthalmology laser company, announced today that the VICTUS Femtosecond Laser Platform received 510(k) clearance from the U.S. Food and Drug Administration.
Researchers at the University of Rochester Medical Center are testing whether different doses of an established blood pressure medication can provide the same benefits as a standard dose in people with mild hypertension, possibly with fewer side effects and at a lower cost. The newly launched clinical trial, funded with a $1.9 million grant from the National Heart Lung and Blood Institute, is the first of its kind in the United States.
Teva Pharmaceutical Industries Ltd. announced today that the U.S. District Court for the District of Nevada has granted Teva's Motion for Summary Judgment with respect to the validity of U.S. Patent No. 7,320,969. In March 2008, Duramed, now Teva Women's Health, brought suit in the District of Nevada against Watson alleging infringement of Teva's patent as a result of Watson's filing of an Abbreviated New Drug Application (ANDA) for Seasonique®.
The use of digital health technologies across health care and drug development has accelerated. A new paper titled "Digital Progression Biomarkers as Novel Endpoints in Clinical Trials: A Multistakeholder Perspective," co-authored by experts across diverse disciplines, highlights how new remote monitoring technologies present a tremendous opportunity to advance digital medicine in health care even further, specifically in Parkinson's disease.
Repros Therapeutics Inc. today announced that the Company is sending a reply to the FDA's Division of Metabolism and Endocrinology Products following the Company's receipt of FDA's comments on the proposed Phase II study of Androxal® (enclomiphene) in the treatment of Type II diabetes under Repros' open IND. On February 2, 2010 the Company announced that Repros received confirmation from the Agency that the new IND is effective.
› Verified 7 days ago
Dr. Edward E Okimoto, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 599 Farrington Hwy, Suite 201, Kapolei, HI 96707 Phone: 808-674-9500 Fax: 808-674-9436 | |
Marcus K. Iwane, M.D. Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Bvld, Kapolei, HI 96707 Phone: 808-432-3600 | |
Dr. Andrea Barrack, MD Gastroenterology Medicare: Not Enrolled in Medicare Practice Location: 599 Farrington Hwy, Suite 201, Kapolei, HI 96707 Phone: 808-674-9500 Fax: 808-674-9436 | |
Ashley K. Morisako, MD Gastroenterology Medicare: Accepting Medicare Assignments Practice Location: 401 Kamokila Blvd, Kapolei, HI 96707 Phone: 808-432-3600 |